In addition to its immunosuppressive activity, HDAC inhibitors block GATA binding protein-1 (GATA-1) gene expression in megakaryocytes and elicit thrombocytopenia. In this report we state that for a given immunosuppressive dose of HDAC inhibitor, the ratio of GATA-1 reporter gene activity relative to IL-2 reporter gene assay (G/I ratio of measured IC 50 ) can be predictive of a HDAC inhibitor's thrombocytopenic effect. This study utilized nine HDAC inhibitors at a minimal effective dose in a rat heterotopic cardiac transplantation model and the resultant G/I ratios and platelet depletion rates were highly correlated (r‫.)339.0؍‬ These results indicate that calculation of G/I ratio can be a novel method for selecting immunosuppressive HDAC inhibitor having minimal thrombocytopenic effect which will benefit the search for new immunosuppressants of greater safety and efficacy.
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate the addition and removal of acetyl groups on specific lysine residues in proteins and maintain a dynamic balance of steady-state protein acetylation. 1, 2) In previous studies, protein hyperacetylation induced by HDAC inhibitors was shown to cause chromatin remodeling, transcriptional activation and repression, cell-cycle arrest, cell differentiation, and cell death. [3] [4] [5] [6] [7] [8] An imbalance between HATs and HDACs resulted in abnormal acetylation patterns of proteins leading to the development of cancer. 4) These observations suggested that HDAC inhibitors may represent a new class of cancer therapy agent.
In addition to antitumor activity, HDAC inhibitors are reported to possess immunosuppressive activity, such as inhibition of lymphocyte proliferation and IL-2 production. [9] [10] [11] [12] [13] [14] [15] The importance of IL-2 down-regulation in preventing acute rejection in organ transplantation and the development of autoimmune diseases has been demonstrated by the therapeutic usefulness of the widely used immunosuppressants cyclosporine A and FK506. Unlike these compounds, the administration of HDAC inhibitors resulted in thrombocytopenia, a common side effect when used in cancer chemotherapy. [16] [17] [18] [19] [20] We recently reported that HDAC inhibitors inhibit GATA binding protein-1 (GATA-1) gene expression in megakaryocytes by decreasing the transactivation function of GATA-1 itself and that this may in turn lead to a delay in megakaryocyte maturation and initiate thrombocytopenia. 21) In this study, nine HDAC inhibitors compounds were administered at an immunosuppressive dose in vivo to investigate the correlation between a ratio of IC 50 value in GATA-1 reporter gene assay to IC 50 value in IL-2 reporter gene assay (G/I ratio) and a HDAC inhibitor's thrombocytopenic effect. [1, 4, 7, 10] tetraazacyclododecine-1,4,7,10(3H,12H)-tetrone.
MATERIALS AND METHODS

Compounds
Plasmid Construction The plasmid pGL3-IL2pro-43 was made by inserting a PCR fragment amplified from Jurkat genomic DNA containing the IL-2 promoter from Ϫ378 to ϩ54, into the NheI-Hind III sites of the pGL3-basic vector (Promega, Madison, WI, U.S.A.). The human IL-2 promoter sequence was obtained from GenBank (Accession Number X67285). The plasmid pGL3-HSI-IE-promoter was made by inserting PCR fragments amplified from Jurkat genomic DNA, containing the human GATA-1 promoter from Ϫ3769 to Ϫ3133 (HSI promoter) and from Ϫ789 to ϩ30 (IE promoter), into the KpnI-NheI and NheI-Hind III sites of the pGL3-basic vector, respectively. The human GATA-1 promoter sequence was obtained from GenBank (Accession Number AF196971). Cell Culture Jurkat cells were maintained in RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, U.S.A.) supplemented with 10% fetal calf serum (Moregate Biotech, Bulimba QLD, Australia), 100 units/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, U.S.A.). Cells were grown at 37°C with 5% CO 2 . For activation of Jurkat cells, phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) and ionomycin (Sigma-Aldrich) were used at final concentrations of 50 ng/ml and 1 mg/ml, respectively. HEL (Japanese Collection of Research Bioresources, Tokyo, Japan) cells, a human erythroleukemia cell line, were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were grown at 37°C with 5% CO 2 .
Reporter Gene Assay In IL-2 reporter gene assays, Jurkat cells (1ϫ10 7 ) were transiently transfected with 1 mg of the plasmid pGL3-IL2pro-43 by electroporation using a GenePulser II (975 microfarads, 300 V; Bio-Rad Laboratories, Hercules, CA, U.S.A.) at 4°C. After 10 h, transfected cells were stimulated with PMA and ionomycin. After 14 h of stimulation, cells were lysed and analyzed using a BrightGlo Luciferase Assay System (Promega) according to the manufacturer's instructions. In a compound treatment study, various concentrations of compounds were added at the time of stimulation. In GATA-1 reporter gene assays, HEL cells (8.75ϫ10 6 ) were transiently transfected with 15 mg of the plasmid pGL3-HSI-IE-promoter or pGL3-HSI(m)-IE(m) by electroporation using GenePulser II (10 microfarads, 1750 V) at 4°C. After 8 h of transfection, cells were lysed and analyzed using a Bright-Glo Luciferase Assay System according to the manufacturer's instructions. In a compound treatment study, various concentrations of compounds were added at 4 h posttransfection.
Cell Viability Assay Cell viability was evaluated by the modified MTT assay using a cell counting kit-8 (Dojindo Laboratries, Kumamoto, Japan) according to the manufacturer's instructions.
Heterotopic Cardiac Transplantation in Rats Heterotopic cardiac allografts were implanted using the cuff technique. Hearts from male ACI rats aged 8 weeks (CLEA Japan Inc., Tokyo, Japan) were removed and implanted into the neck of male Lewis rats aged 8 weeks (Charles River Japan Inc., Kanagawa, Japan). Anesthesia was conducted with 40 mg/kg phenobarbital intraperitoneally. The recipients whose heartbeats stopped within 3 d after grafting or which died with living grafts were excluded from analysis. Each of nine compounds tested was dissolved in 10% aqueous HCO-60 (Nikko Chemicals, Tokyo, Japan) or 10% HCO-60/saline, and given by singly daily oral administration or subcutaneous injection for 14 consecutive days beginning at the next day of transplantation.
HDAC Inhibitor-Induced Thrombocytopenia in Rats Male Lewis rats aged 8 weeks were used. Each of nine compounds tested was dissolved in 10% aqueous HCO-60 (Nikko Chemicals, Tokyo, Japan) or 10% HCO-60/saline, and given by single daily oral administration or subcutaneous injection for 7 consecutive days. At 3 h after administration on the final day, the animals were anaesthetized with phenobarbital and blood was taken to measure platelet counts with a haematology analyzer. Platelet depletion rates in compound-treated animals were calculated as a percent reduction in platelet counts compared to vehicle-treated animals. Namely, a high platelet depletion rate indicates a high toxicity in animals.
RESULTS AND DISCUSSION
In this study, we provide evidence that GATA-1/IL-2 (G/I) ratio can be a predictive value of HDAC inhibitor's thrombocytopenic effect at an immunosuppressive dose.
We first evaluated the immunosuppressive effects of nine HDAC inhibitors in a rat heterotopic cardiac transplantation model. Hearts from male ACI rats were removed and implanted into the neck of male Lewis rats. Each of the nine compounds tested was given by single daily oral administration or subcutaneous injection for 14 consecutive days beginning the day after transplantation. As shown in Table 1 , all of these nine compounds prolonged heart allograft survival in rat, and each compound's minimal effective dose was estimated at the dose which produces over 8 d of the median graft survival time (MST).
We next assessed the thrombocytopenic effects of the nine HDAC inhibitors. Each compound tested was given by single daily oral administration or subcutaneous injection for 7 consecutive days at a minimal effective dose in a rat heterotopic cardiac transplantation model. Platelet counts were measured with a haematology analyzer on the final day. As shown in Table 2 , these nine compounds showed a variety of thrombocytopenic effects at a minimal effective dose in a rat heterotopic cardiac transplantation model (Platelet depletion rates relative to vehicle control were 8.5-75%). In this experiment, variances of platelet counts in each group were very small as previously reported. 21) Regarding a difference in the compounds' treatment protocol between the transplant experiment and the haematologic study (14 consecutive days vs. 7 consecutive days), we have confirmed that there is no difference in the platelet depletion rates between the 7-d treatment and the 14-d treatment.
Previously, we have shown that HDAC inhibitors inhibit IL-2 gene expression in T cells and possess immunosuppressive activity in vivo. [12] [13] [14] [15] Furthermore, we have also demonstrated that HDAC inhibitors inhibit GATA-1 gene expression in megakaryocytes and cause thrombocytopenia. 21) We therefore assume that the HDAC inhibitor's thrombocytopenic effect at an immunosuppressive dose can be predicted by in vitro analysis using GATA-1 and IL-2 reporter gene assays. We then performed GATA-1 reporter gene assay in human megakaryocytic HEL cells and IL-2 reporter gene assay in Jurkat cells to determine IC 50 values of the nine HDAC inhibitors in each assay, and calculated G/I ratio. As a result, the administration of the nine HDAC inhibitor compounds showed a variety of G/I ratios (Table 3 ) which highly correlated with those compounds' thrombocytopenic effects at a minimal effective dose in a rat heterotopic cardiac transplantation model (rϭ0.933, Fig. 1 ). In these assays, cell viability was not influenced by all of the nine HDAC inhibitors at all concentrations tested (data not shown).
In this study, we used G/I ratio to predict HDAC inhibitor's thrombocytopenic effect at an immunosuppressive dose. Because each compound has different chemical and physical properties that affect pharmacokinetic profiles in vivo, including bioavailability, it is still difficult to directly predict the in vivo effects using in vitro assays (e.g., in vivo immunosuppression vs. in vitro IL-2 inhibition). Therefore, to overcome this problem, we used two parameters in both in vitro and in vivo experiments. Each of these parameters possesses several variances, especially in estimation of minimal effective dose in a rat heterotopic cardiac transplantation model from MST. However, even if the variance of each parameter is taken into account, our results still show that the correlation between G/I ratio and thrombocytopenic effect at a minimal effective dose in a rat heterotopic cardiac transplantation model would be exactly high and the G/I ratio is enough to predict which compound we should select as an immunosuppressant with minimal thrombocytopenia.
In conclusion, these results support the model that HDAC inhibitors cause immunosuppression and thrombocytopenia in vivo by targeting IL-2 and GATA-1, respectively, and indicate that calculation of the G/I ratio can be a novel method for selecting an immunosuppressive HDAC inhibitor having little thrombocytopenic effect. The application of this method will be useful for the production of safer and thus more effective immunosuppressants. a) Median graft survival time. b) Platelet counts were measured using a haematology analyzer (nϭ4 in each group, S.E.M. never exceeded 10%). Values were calculated as a percent reduction in mean platelet counts compared to vehicle-treated group. a) Inhibition of IL-2 promoter activity in Jurkat cells stimulated with PMA/ionomycin. Values were calculated from two or three independent experiments performed in triplicate with similar results (S.E.M. never exceeded 25%). b) Inhibition of GATA-1 promoter activity in HEL cells. Values were calculated from two or three independent experiments performed in triplicate with similar results (S.E.M. never exceeded 25%).
